-
- Nitta Kosaku
- Department of Medicine, Kidney Center, Tokyo Women's Medical University, Japan
-
- Yajima Aiji
- Department of Medicine, Kidney Center, Tokyo Women's Medical University, Japan
-
- Tsuchiya Ken
- Department of Blood Purification, Kidney Center, Tokyo Women's Medical University, Japan
書誌事項
- 公開日
- 2017
- 資源種別
- journal article
- DOI
-
- 10.2169/internalmedicine.8618-16
- 公開者
- 一般社団法人 日本内科学会
この論文をさがす
説明
<p>Chronic kidney disease (CKD) patients with coexisting osteoporosis are becoming common. Many of the therapeutic agents used to treat osteoporosis are known to be affected by the renal function. It is generally thought that osteoporosis in G1 to G3 CKD patients can be treated as in non-CKD patients with osteoporosis. In stage 4 or more advanced CKD patients and CKD patients on dialysis with osteoporosis, however, bisphosphonates must be used with caution, bearing in mind the potential development of such disorders as adynamic bone disease. The use of vitamin D preparations in low doses is relatively safe. In postmenopausal women, raloxifene must be administered with caution. When using denosumab, the serum calcium concentrations should be monitored carefully to prevent the development of hypocalcemia, and active vitamin D preparations should be administered concomitantly. The present article provides an overview of the management of osteoporosis in CKD patients. </p>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 56 (24), 3271-3276, 2017
一般社団法人 日本内科学会
